NEW YORK (GenomeWeb News) – The Centre of Excellence for the Prevention of Organ Failure (PROOF) has teamed up with the Allergy, Genes and Environment Network of Centres of Excellence (AllerGen NCE) to develop blood-based tests intended to be used in clinical trials of drugs for allergic diseases
NEW YORK (GenomeWeb News) – Merck Serono, the biopharmaceutical division of Merck KGaA, today said that it has spun out a bioinformatics firm, Quartz Bio, from its Entrepreneur Partnership Program launched earlier this year.
NEW YORK (GenomeWeb News) – The UK's University of Leicester has received a £7 million ($10.9 million) grant from the John and Lucille van Geest Foundation that it will use to build a new biomarker lab and to fund an array of cardiovascular research projects, the university said today.
NEW YORK (GenomeWeb News) – Population Genetics Technologies said today that it has partnered with the University of Cambridge's Autism Research Centre to study variants in two genes that previously have been associated with Asperger syndrome.
NEW YORK (GenomeWeb News) – Plexpress today announced it has partnered with Phalanx Biotech Group to offer a new service allowing researchers to discover, select, and validate biomarkers in a streamlined integrated workflow.
NEW YORK (GenomeWeb News) – KineMed today reported the Michael J. Fox Foundation has awarded it an additional $1.2 million to continue development of kinetic biomarkers for Parkinson's disease.
NEW YORK (GenomeWeb News) – The British non-profit Parkinson's UK plans to provide £750,000 ($1.2 million) for research to find protein biomarkers for diagnosing and measuring the progress of Parkinson's disease.
NEW YORK (GenomeWeb News) – Berg Pharma will use its Integrative Biology platform to identify drug targets and biomarkers in clinical samples from the Parkinson's Institute of Sunnyvale, Calif., under a partnership announced today.
NEW YORK (GenomeWeb News) – Scienion US said today that array firm Courtagen Life Sciences will use Scienion's sciFlexArrayer technology to produce biochips for use with its Avantra Q400 Biomarker Workstation.
NEW YORK (GenomeWeb News) – Merck Serono and Compugen jointly announced today the formation of a new biomarker discovery firm focused on prediction of drug-induced toxicity.
In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.
